Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons dr. M. Nijland

Publicaties

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma

MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis

Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics

Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives

Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma

Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment

Pers/media

La consolidation de l’atezolizumab impressionne dans le DLBCL à haut risque

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018